BMRN 241220 57.50P (BMRN241220P57500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BMRN241220P57500

Watchlist

0.05
-0.09-64.29%

15min DelayTrading Dec 16 11:07 ET

0.05High0.05Low

Intraday

5D
Daily

News

Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target
BenzingaDec 12 11:47 ET
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Yahoo FinanceDec 11 05:14 ET
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
Seeking AlphaDec 5 13:26 ET
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
Moomoo NewsDec 5 11:31 ET · Ratings
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Moomoo NewsDec 5 11:31 ET · Ratings
Biomarin Pharmaceutical To Present At Evercore ISI HealthCONx Conference; Webcast At 10:00 AM ET
RTTNewsDec 4 09:04 ET

Comments

Moomoo AI

Mar 25 07:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

Moomoo AI

Mar 7 07:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Moomoo AI

Feb 8 08:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Jan 18 06:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 21, 2023 10:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts